Pyxis Oncology is trading 11.02% lower at $2.87 as broader biotech and macroeconomic pressure weigh on shares; no new company-specific announcement emerged to explain the decline.
- XBI is down 2.04% as rising Treasury yields, elevated oil prices, and renewed inflation concerns weigh on growth-oriented healthcare equities.
- Pyxis Oncology’s most recent major update was positive Phase 1 MICVO data announced September 9; the evidence points to sector and macroeconomic selling, not negative company-specific news.